Bailard, Inc. Esperion Therapeutics, Inc. Transaction History

Bailard, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $113,400 - $213,700	-10,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$19.4 - $28.71 $252,199 - $373,230	-13,000 Reduced 56.52%	10,000 $212,000
Q4 2020 Feb 03, 2021	SELL	$24.2 - $35.76 $1.83 Million - $2.7 Million	-75,500 Reduced 76.65%	23,000 $598,000
Q2 2020 Aug 12, 2020	BUY	$30.04 - $51.31 $156,208 - $266,812	5,200 Added 5.57%	98,500 $5.05 Million
Q1 2020 Apr 16, 2020	BUY	$27.44 - $73.84 $93,296 - $251,056	3,400 Added 3.78%	93,300 $2.94 Million
Q4 2019 Jan 31, 2020	SELL	$35.4 - $59.82 $35,400 - $59,820	-1,000 Reduced 1.1%	89,900 $5.36 Million
Q3 2019 Oct 18, 2019	BUY	$34.47 - $47.53 $506,709 - $698,691	14,700 Added 19.29%	90,900 $3.33 Million
Q2 2019 Jul 26, 2019	BUY	$40.1 - $52.33 $669,670 - $873,911	16,700 Added 28.07%	76,200 $3.55 Million
Q1 2019 Apr 24, 2019	BUY	$40.11 - $53.57 $2.03 Million - $2.71 Million	50,500 Added 561.11%	59,500 $2.39 Million
Q2 2018 Aug 08, 2018	SELL	$36.2 - $76.4 $1.82 Million - $3.84 Million	-50,300 Reduced 84.82%	9,000 $353,000
Q1 2018 May 07, 2018	SELL	$65.94 - $80.76 $1.06 Million - $1.29 Million	-16,000 Reduced 21.25%	59,300 $4.29 Million
Q4 2017 Feb 08, 2018	BUY	$43.47 - $67.43 $521,640 - $809,160	12,000 Added 18.96%	75,300 $0
Q2 2017 Aug 11, 2017	BUY	N/A	22,300 Added 54.39%	63,300 $0
Q1 2017 Jan 29, 2018	BUY	N/A	32,000 Added 355.56%	41,000 $1.45 Million
Q4 2015 Jan 29, 2018	BUY	N/A	9,000	9,000 $0

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.